NeuroMed “BLT” Variety Analgesic

Pack

Your Comprehensive Topical Pain Management Solution

Compounded BLT – the high risk option• Drug diversion Exposure to the consequences of drug diversion – procuring,

using and passing a prescription drug ordered for one patient but used on others and supplied to other clinicians is, in fact, illegal drug diversion!• Cross contamination Using multi-use containers on multiple patients exposes

patients to the risk of cross contamination• Wasting time Time wasted waiting 45 – 60 minutes or more for anesthetic action

decreases practice revenue by tying up treatment rooms and clinicians• Cumulative systemic absorption risk Exposing patients to anesthetic on the skin

over a prolonged period of time increases risk of cumulative systemic absorption

NeuroMed BLT – the solution option• Eliminate legal exposure - NeuroMed BLT is a variety package that contains benzocaine

(20%), lidocaine (4%) and tetracaine (2%) – each is OTC with no prescription required – all products packaged together for convenience and to allow clinician application flexibility• Eliminate cross contamination risk - Each of the included anesthetic analgesics is packaged

in single-use, metered dosed, sanitary packets for precision and reduction in cross contamination risk• Reduce onset wait time - NeuroMed products all include a proprietary formulation

designed to improve onset and efficacy – speeding onset and reducing treatment time improves productivity and practice revenue • Reduce systemic absorption risk - Reducing anesthetic analgesic time on skin may reduce

the risk of cumulative systemic absorption – in an IRB approved study of the NeuroMed lidocaine product which included 239 human test subjects – no active lidocaine nor its active metabolite MEGx entered the blood in even a single subject after multiple applications in an 8 hour period

Contents

3 boxes each of 25 single-use, sanitary packets per product:

• Benzocaine 20% / 25 – 3 ml packet (NeuroMed FA)

• Lidocaine 4% / 25 – 4 ml packet (NeuroMed 7)

• Tetracaine 2% / 25 – 3 ml packet (NeuroMed LA)

Contents

Description and Explanation

• All include the standard Sambria Pharmaceuticals’ proprietary formulation designed to improve delivery and rate of onset of the active pharmaceutical ingredients (API’s) – the key technology used to create stark product differentiation.

• Each type of anesthetic analgesic is packaged separately in individual 3-ml packets (4-ml for lidocaine). Each anesthetic analgesic is packaged in boxes of 25 units per box for a total combined 250 grams of product.

• All three boxes are wrapped in a single, combination variety package for clinician convenience and ease of shipping.

Description and Explanation

• Clinicians are provided with the option of choosing the appropriate anesthetic analgesic commensurate with specific applicable uses.• This combination variety package also provides three individual API’s

which allow clinicians to use singly or otherwise as deemed medically necessary at clinician discretion in a regulatory complaint manner• For additional convenience, each individual 3-milliliter sanitary, single-

use packet (lidocaine – 4-ml) is supplied as a metered dose application for dosing precision and wastage minimization.

Product Advantages

• Sanitary dose packaging• Precision metered dose packaging • Formulated to improve onset and efficacy• Modular multiple options – fast-acting to long-lasting depending on anesthetic

analgesic application• Increased therapeutic flexibility• Designed to improve safety profile (in IRB approved study of the lidocaine product –

among 239 human test subjects none demonstrated plasma lidocaine in the blood up to 12 hours after initial application)• Cost-effective - competitively priced (MSRP - only $0.80 per gram to clinical customer)

Samples packets are supplied three to a stip. Each strip has a perforation in between to separate one from the other. Each individual packet includes its own specific data box on the back of the package. The three combined packets have a single tear off tab at the top for easy access and administration.

Samples

• Lidocaine-containing products play an integral role in cutaneous anesthesia by providing patient comfort with minimal side effects. Careful attention must be paid to the particular anatomic location, the total surface area covered, and the duration of anesthetic skin contact

• By reducing the duration of anesthetic contact with skin, clinicians can potentially decrease the risk of cumulative anesthetic dose entry into the blood – NeuroMed brand topical anesthetics repeatedly demonstrate reduced time to onset and peak action anecdotally

• This variety package has the potential to provide a strong solution to the regulatory obstacles currently presented by the uniformly non-compliant vast pharmaceutical compounding marketplace (in particular, anticipatory compounding and widespread clinician diversion)

• Sambria Pharmaceuticals is the first to market a comprehensive multi-API solution in a regulatory compliant manner • In instances where clinicians choose to combine two or three API’s, it is highly unlikely that any single API product

will match efficacy. At minimum safety profiles will not exceed those of currently marketed compounded products due to the reduced time of contact on the skin. IRB approved study of the lidocaine product presented no active lidocaine nor its primary metabolite MEGX found in blood samplings among 239 human test subjects when drawn at multiple intervals

• Unique metered dosed, sanitary packaging also provides for wastage minimization as well as more precise dosing when compared to tube or jar packaging

Opportunity

Regulatory Compliance

Products are regulated by, marketed and manufactured in accordance with the 21 CFR 348 Monograph OTC Topical Analgesics and Anesthetics.

THANK YOU FOR YOUR TIME AND CONSIDERATION

www.sambriapharma.cominfo@sambriapharma.com888.246.6601